ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARDELYX, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.09+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $766.53M
- P/E (TTM)
- –
- Dividend yield
- –
ARDELYX, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $377.81M | $319.20M | $82.53M | $15.60M | $0 | $0 | – | – | – | – | 92.8% | +18.4% |
| IBSRELA | $274.21M | $158.29M | $80.06M | $15.60M | $0 | – | – | – | – | – | 67.3% | +73.2% |
| XPHOZAH | $103.60M | $160.91M | $2.46M | $0 | $0 | – | – | – | – | – | 25.4% | -35.6% |
| Product supply revenue | $15.88M | $11.65M | $6.12M | $1.53M | $907.00K | $1.50M | $322.00K | – | – | – | 3.9% | +36.3% |
| Non-cash royalty revenue related to the sale of future royalties | $8.55M | $2.69M | $0 | $0 | – | – | – | – | – | – | 2.1% | +217.4% |
| Licensing revenue | $5.09M | $78.00K | $35.81M | $35.03M | $5.01M | $706.00K | $4.50M | $2.32M | $42.00M | – | 1.2% | +6423.1% |
| Other | – | – | – | – | – | – | $322.00K | $287.00K | – | – | – | – |
| Other cost of revenue | – | – | – | – | – | $1.50M | $322.00K | $287.00K | – | – | – | – |
| Collaborative development revenue | – | – | $0 | $0 | $4.18M | $5.36M | $459.00K | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $377.81M | $319.20M | $83.28M | $15.60M | $0 | $0 | $0 | – | – | – | 92.8% | +18.4% |
| Asia Pacific | $29.17M | $14.34M | $41.12M | $31.00K | $10.08M | $6.77M | $5.28M | $287.00K | $42.00M | – | 7.2% | +103.4% |
| North America | $342.00K | $78.00K | $59.00K | $36.53M | $13.00K | $806.00K | – | $2.32M | – | – | 0.1% | +338.5% |
| Sweden | – | – | – | – | – | – | – | – | – | $24.00M | – | – |
| Europe | – | – | – | – | – | – | – | – | – | $24.03M | – | – |
| China | – | – | – | – | – | – | $3.00M | – | $12.00M | – | – | – |
| Japan | – | – | – | – | – | – | $800.00K | – | $30.00M | – | – | – |
| Hong Kong SAR China | – | – | – | – | – | – | $1.50M | – | – | – | – | – |
| Canada | – | – | – | $31.00K | $13.00K | $806.00K | $0 | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Ardelyx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.